Role of PET/CT in the era of immune checkpoint inhibitors: state of art.
Immune checkpoint inhibitors (ICI) have achieved astonishing results and improved overall survival (OS) in several type of malignancies, including advanced melanoma. However, due to the peculiar type of anti-cancer activity provided by these drugs, the response patterns during ICI treatment can be completely different from that seen with "old" chemotherapeutic agents. To provide an overview of the available literature and potentials of 18F-FDG PET/CT in advanced melanoma during the course of therapy with ICI in the context of treatment response evaluation. Morphologic criteria, expressed by Response Evaluation Criteria in Solid Tumors (RECIST), immune-related response criteria (irRC), irRECIST, and, more recently, immune-RECIST (iRECIST), along with response criteria based on metabolic parameters with 18F-Fluorodeoxyglucose (18F-FDG), have been explored. To overcome the limits of traditional response criteria, new metabolic response criteria have been introduced on time and are being continuously updated, such as the PET/CT Criteria for early prediction of Response to Immune checkpoint inhibitor Therapy (PECRIT), the PET Response Evaluation Criteria for Immunotherapy (PERCIMT), and "immunotherapy-modified" PET Response Criteria in Solid Tumors (imPERCIST). The introduction of new PET radiotracers, based on monoclonal antibodies combined with radioactive elements ("immune-PET"), appears of great interest. Although the role of 18F-FDG PET/CT in malignant melanoma has been widely validated for detecting distant metastases and recurrences, evidences in course of ICI are still scarce and larger multicenter clinical trials are needed.